Anticorps Monoclonal anti-NeutraKine® IL-6

NeutraKine® IL-6 Monoclonal Antibody for IHC, Neutralization, ELISA

Hôte / Isotype

Mouse / IgG1

Réactivité testée

Humain et plus (1)

Applications

IHC, IF, Neutralization, ELISA

Conjugaison

Non conjugué

Publications(10)

CloneNo.

4G3E6

N° de cat : 69001-1-Ig

Synonymes

IL6, IL-6, 4G3E6, B-cell stimulatory factor 2, IFN-beta-2

---

Galerie de données de validation

• 

  Neutralization experiment of NeutraKine® IL-6 using 69001-1-Ig

  Recombinant human IL-6 (Cat.NO. HZ-1019) stimulates proliferation of hybridoma (Proteintech mouse anti-GST clone 3G12B10) in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human IL-6 (1 ng/mL HZ-1019) is neutralized by mouse anti-human IL-6 monoclonal antibody 69001-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 10-30 ng/mL.

• 

  Neutralization experiment of NeutraKine® IL-6 using 69001-1-Ig

  Recombinant human IL-6 (Cat.NO. HZ-1019) stimulates proliferation of hybridoma (Proteintech mouse anti-GST clone 3G12B10) in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human IL-6 (1 ng/mL HZ-1019) is neutralized by mouse anti-human IL-6 monoclonal antibody 69001-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 3-15 ng/mL. The NeutraControl mouse anti-human IL-6 monoclonal antibody 69501-1-Ig could recognize human IL-6 but could not neutralize human IL-6 activity in the range of 0.06 ng/mL-1000 ng/mL (green curve, refer to top X-right Y axis).

• 

  IHC staining of human tonsillitis using 69001-1-Ig

  Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 69001-1-Ig (NeutraKine® IL-6 antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human tonsillitis using 69001-1-Ig

  Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 69001-1-Ig (NeutraKine® IL-6 antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Neutralization

Applications publiées

• IF: See 1 publications below
• ELISA: See 1 publications below

Informations sur le produit

69001-1-Ig cible NeutraKine® IL-6 dans les applications de IHC, IF, Neutralization, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: rat, Humain
• Hôte / Isotype: Mouse / IgG1
• Clonalité: Monoclonal
• Type: Anticorps
• Immunogène: human Humankine IL-6 protein HZ-1019
• Nom complet: interleukin 6 (interferon, beta 2)
• Symbole du gène: IL6
• Identification du gène (NCBI): 3569
• Conjugaison: Non conjugué
• Forme: Lyophilized Powder
• Méthode de purification: Purification par protéine G
• Tampon de stockage: Sterile PBS
• Endotoxin: <0.1 EU/μg
• Reconstitution: This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.
• Stability and Storage: Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.

Informations générales

Interleukin-6 (IL-6) is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. IL-6 protein is secreted by a variety of cell types including T cells and macrophages as phosphorylated and variably glycosylated molecule. IL-6 plays an essential role in the final differentiation of B-cells into Ig-secreting cells involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. IL-6 is also considered a myokine, a cytokine produced from muscle, and is elevated in response to muscle contraction. IL-6 has been shown to interact with interleukin-6 receptor and glycoprotein 130. Additionally, IL-6 is involved in hematopoiesis, bone metabolism, and cancer progression, and has been defined an essential role in directing transition from innate to acquired immunity.

This antibody can be used to neutralize the bioactivity of IL-6.

Publications

Species	Application	Title
human	Neutralization	Oncogene; LncRNA XIST regulates breast cancer stem cells by activating proinflammatory IL-6/STAT3 signaling; Authors - Yuxi Ma
human	IF	Front Immunol; Expression and clinical significance of interleukin-6 pathway in cholangiocarcinoma; Authors - Dongqing Gu
human	ELISA	Free Radic Biol Med; IRF1/ZNF350/GPX4-mediated ferroptosis of renal tubular epithelial cells promote chronic renal allograft interstitial fibrosis; Authors - Yao Zhang
human	Neutralization	Int J Biol Sci; The RNF26/CBX7 axis modulates the TNF pathway to promote cell proliferation and regulate sensitivity to TKIs in ccRCC.; Authors - Wentao Liu
human	Neutralization	Biomed Pharmacother; Interleukin-6 neutralizing antibody attenuates the hypersecretion of airway mucus via inducing the nuclear translocation of Nrf2 in chronic obstructive pulmonary disease.; Authors - Yuan-Yuan Wei
rat		J Biochem Mol Toxicol; Uric acid promotes interleukin-17 expression to cause kidney injury; Authors - Lina Yang

{{ptg:RelatedPrimaryAntibodies}}